Literature DB >> 10881834

Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients.

C L Lau1, S M Palmer, K E Posther, D N Howell, N L Reinsmoen, H T Massey, V F Tapson, J J Jaggers, T A D'Amico, R D Davis.   

Abstract

BACKGROUND: Panel-reactive antibody (PRA) is used to estimate the degree of humoral sensitization in the recipient before transplantation. Although pretransplant sensitization is associated with increased complications in other solid organ transplant recipients, less is known about the outcome of sensitized lung transplant recipients. Therefore, we sought to determine the impact of elevated pretransplant PRA on clinical outcomes after lung transplantation.
METHODS: The records of the first 200 lung transplant operations performed at Duke University Medical Center were reviewed. The outcomes of sensitized patients, PRA greater than 10% before transplantation (n = 18), were compared with the outcomes of nonsensitized patients.
RESULTS: Sensitized patients experienced a significantly greater number of median ventilator days posttransplant (9 +/- 8) as compared with nonsensitized recipients (1 +/- 11; p = 0.0008). There were no significant differences between the number of episodes of acute rejection; however, there was a significantly increased incidence of bronchiolitis obliterans syndrome occurring in untreated sensitized recipients (56%) versus nonsensitized (23%; p = 0.044). In addition, there was a trend towards decreased survival in the sensitized recipients, with a 2-year survival of 58% in sensitized recipients as compared with 73% in the nonsensitized patients (p = 0.31).
CONCLUSIONS: Sensitized lung transplant recipients experience more acute and chronic complications after transplantation. These patients probably warrant alternative management strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881834     DOI: 10.1016/s0003-4975(00)01224-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Association between Allosensitization and Waiting List Outcomes among Adult Lung Transplant Candidates in the United States.

Authors:  Laneshia K Tague; Chad A Witt; Derek E Byers; Roger D Yusen; Patrick R Aguilar; Hrishikesh S Kulkarni; Karen Bennett Bain; Keith A Fester; Varun Puri; Daniel Kreisel; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem
Journal:  Ann Am Thorac Soc       Date:  2019-07

Review 2.  [Lung transplantation and rejection. Basic principles, clinical aspects and histomorphology].

Authors:  J Wohlschläger; U Sommerwerck; D Jonigk; J Rische; H A Baba; K M Müller
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

3.  The impact of pre-transplant allosensitization on outcomes after lung transplantation.

Authors:  James P Bosanquet; Chad A Witt; Bradford C Bemiss; Derek E Byers; Roger D Yusen; Alexander G Patterson; Daniel Kreisel; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem
Journal:  J Heart Lung Transplant       Date:  2015-06-10       Impact factor: 10.247

Review 4.  Human leukocyte antigen antibodies for monitoring transplant patients.

Authors:  Junchao Cai; Paul I Terasaki
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.

Authors:  Laurie D Snyder; Ziwei Wang; Dong-Feng Chen; Nancy L Reinsmoen; C Ashley Finlen-Copeland; W Austin Davis; David W Zaas; Scott M Palmer
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

6.  The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.

Authors:  Xiaoqin Hua; Tobias Deuse; Yi-Je Chen; Heike Wulff; Mandy Stubbendorff; Ralf Köhler; Hiroto Miura; Florian Länger; Hermann Reichenspurner; Robert C Robbins; Sonja Schrepfer
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

7.  Dynamics of human regulatory T cells in lung lavages of lung transplant recipients.

Authors:  David C Neujahr; Adriana C Cardona; Onome Ulukpo; Mark Rigby; Andres Pelaez; Allan Ramirez; Anthony A Gal; Seth D Force; E Clinton Lawrence; Allan D Kirk; Christian P Larsen
Journal:  Transplantation       Date:  2009-08-27       Impact factor: 4.939

8.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Methods Mol Biol       Date:  2013

9.  Pre-transplant Panel Reactive Antibody and Survival in Adult Cystic Fibrosis Patients After Lung Transplantation.

Authors:  Don Hayes; Dmitry Tumin; Joseph D Tobias
Journal:  Lung       Date:  2016-03-02       Impact factor: 2.584

10.  Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction.

Authors:  Takekazu Iwata; Alexander Philipovskiy; Amanda J Fisher; Robert G Presson; Masako Chiyo; Jae Lee; Elizabeth Mickler; Gerald N Smith; Irina Petrache; David B Brand; William J Burlingham; Bagavathi Gopalakrishnan; Daniel S Greenspan; Jason D Christie; David S Wilkes
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.